Item 3.02 Unregistered Sale of
On
Proceeds from the Series B offering are expected to be used to fund the Company's upcoming clinical trials for its flagship drug candidate Samarium-153-DOTMP (aka CycloSam®), as well as for general working capital and overhead.
The shares of Series B Preferred Stock are convertible into an aggregate of
approximately 16.6 million shares of common stock of the Company ("Common
Stock") and will have voting rights alongside Common Stock holders on an
as-converted basis. The terms of the Series B Convertible Preferred Stock are
fully described in the Company's Certificate of Designation filed in an 8-K
dated
Investors in the offering also received six-month, non-registered warrants to
purchase an aggregate of up to 5.8 million shares of Common Stock at
The shares of Series B Convertible Preferred Stock and the Warrants issued under this private placement were not registered under the Securities Act, 1933, as amended, but were issued in reliance on an exemption from registration set forth in Section 4(a)(2) of the Securities Act and/or Regulation D thereunder.
Item 8.01 Other Items
On
On
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit Description Number 3.1 Certificate of Designation for the Series B Convertible Preferred Stock is incorporated by reference to Exhibit 3.1 of our Form 8-K datedDecember 31, 2020 10.1 Form of Securities Purchase Agreement for Series B Convertible Preferred Stock 10.2 Form of Warrant for the Purchase of Shares of Common Stock 99.1 Press release issued onJanuary 28, 2021 2
© Edgar Online, source